基本信息
浏览量:38
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Fernando Torres Andón is Miguel Servet Researcher at the Oncology Department INIBIC/CHUAC (A Coruña, Spain) particularly focused on Antitumoral Immunotherapy: reprogramming tumor-associated macrophages using nanomedicines with diagnostic and therapeutic purposes.
Dr. Andón holds a degree in Pharmacy by the University of Santiago de Compostela (Spain, 2003). He performed his European Ph.D. Thesis, “Evaluation of new compounds as potential anti-leukaemia agents” at ULPGC (Spain, 2010) under the supervision of Prof. Estévez, including a stay of 3 months in Breard’s lab at University Paris Sud 11 (France, 2008). He achieved a “Master Degree in Bioinformatics” by the UNIA (Spain, 2010). This work focused on the antitumoral evaluation of natural compounds (i.e. flavonoids or lactones) was published in 10 scientific articles in the area of cancer and cell death signaling. He was awarded the Outstanding PhD thesis in Health Sciences and Best PhD thesis in Health Sciences in 2010.
Dr. Andón performed his first postdoc in Nanotoxicology at Karolinska Institutet (Sweden, 2011-2013), under the supervision of Prof. Fadeel, studying the Interactions between Nanomaterials and the Immune System. His work in the FP7-NANOMMUNE and FP7-MARINA implied the coordination of the “in vitro toxicological evaluation of nanomaterial related effects in humans”. These studies demonstrated the ability of eosinophils to degrade carbon nanotubes (CNTs), in vitro and ex vivo. His collaborative studies showed the ability of all human peroxides (MPO, EPO and LPO) to biodegrade CNTs. He published 6 original manuscripts, 5 invited comments in the field of nanomedicine (2012), 1 invited comment in ACSnano 2017 about the use of CNTs as optical sensors, and 2 reviews in high impact journals detailing the effects of nanomaterials on our immune system. His work revealed the mechanism of sensing of CNTs by TLRs on the surface of macrophages (Mukherjee et al 2018), inflammasome activation by hollow carbon spheres (Andon et al 2017), or secretion of chemokines by CNTs at sub-lethal doses (Keshavan et al 2021). In 2013, his work was recognized with the Award to the Best Professional Career by "Fundación Barrié".
In 2014, Dr. Andón started his work on the development of novel Therapeutic Nanostructures to Target and Reprogram Tumor Associated Macrophages (TAMs), with the support of leading experts in the fields of Cancer Immunotherapy (Prof. Mantovani/Prof. Allavena ICH, Italy) and Nanomedicine (Prof. Alonso, USC, Spain). He received the Award to the Best Project in Oncology by Novartis Biocamp Italy in 2014; the Marie Skłodowska-Curie Individual European Fellowship (H2020-NANOTAM-2015-2017) and the AECC Investigator Research Grant (2018-2022) for the project "Enhancing the effect of Cancer Immunotherapy through the Re-education of Tumor Associated Macrophages with Nanomedicines”. Dr. Andón has been vice-coordinator of the 2-INTRATARGET and 2^2-INTRATARGET projects (EURONANOMEDIII), focused in the development and evaluation of nanoparticles loaded with biological drugs (i.e. RNA or mAbs) for cancer immunotherapy, comprising 5 EU partners (2018-2021; 2021-2024). In the frame of this projects, his original work demonstrated in vitro the superior ability of poly(I:C) versus imiquimod to polarize macrophages towards M1-antitumoral effector cells (Maeda et al 2019), and also the development and evaluation of arginine-based poly(I:C)-nanocomplexes achieving higher uptake and macrophage-mediated antitumoral efficacy in vitro (Dacoba et al 2020). More recently, Dr. Andón coordinated a work revealing in vivo the superior activity of the combination of poly(I:C) and resiquimod versus the combination with imiquimod to trigger TAMs for effective systemic antitumoral immunity through STAT1 activation (Anfray et al 2021): controlling the sustained activation of innate and adaptive immune responses, resulting in inhibition of tumor growth, prevention of metastasis and furnishment of antitumor immune memory. This is his main line of research, currently continued by Dr. Andón with his Miguel Servet Grant at INIBIC/CHUAC.
Since 2019, Dr. Andón is also collaborating in the H2020-MEFISTO project, with the in vitro immunotoxicological evaluation and efficacy of nanoparticles loaded with anti-inflammatory drugs (Ummarino et al 2020).
During his professional career, Dr. Andón has conducted research in 6 different countries (Italy, France, Netherlands, Sweden, Portugal, Spain). At September 2023, Fernando Torres Andón is the Author of 46 peer-reviewed scientific publications with H index of 22, attracting 2055 citations (updated info in: http://scholar.google.com/citations?user=wLduBTgAAAAJ). 21 publications with Q1, first author in 15 and corresponding in 9 articles.
研究兴趣
论文共 62 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clement Anfray, Carmen Fernandez Varela,Aldo Ummarino,Akihiro Maeda,Marina Sironi,Sara Gandoy,Jose Brea,Maria Isabel Loza,Sergio Leon,Alfonso Calvo,Juan Correa, Eduardo Fernandez-Megia,
FRONTIERS IN IMMUNOLOGY (2024): 1334800-1334800
Fernando Torres Andon,Alba Pensado-López,Clement Anfray,Aldo Ummarino,Iago Fernández-Mariño, Lucia Sanjurjo,Jose Crecente-Campo,Eduardo Fernández-Megía, Flavia Castro, Maria Jose Oliveira,Alfonso Calvo, Rosario García Campelo,
Cancer Researchno. 6_Supplement (2024): 715-715
Alba Pensado-López,Aldo Ummarino, Sophia Khan,Anna Guildford, Iain U Allan,Matteo Santin,Nathalie Chevallier, Elina Varaillon,Elizaveta Kon,Paola Allavena,Fernando Torres Andón
Nanomedicine : nanotechnology, biology, and medicine (2023): 102719-102719
Cancer Researchno. 7_Supplement (2023): 5140-5140
Cancer Researchno. 7 (2023): 5140-5140
Research Square (Research Square) (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn